Why Mankind, Dr Reddy’s and PE firms are so interested in low-profile BSV

Image credit: Compiled by Manali Ghosh via AI

Synopsis
Advent controlled-BSV has charted an exceptional turnaround over the last five years, seeing a 3x jump in its valuation. Its specialised products in women’s health and a robust research pipeline makes it a cynosure of all eyes. As the bidding race to buy BSV intensifies, ET Prime explains the company’s journey and its outlook.

“They gave us a tough fight.” Pithy words from a senior executive at a European drug maker with a portfolio of women’s health products sums up the point. His reference is to BSV, formerly Bharat Serums and Vaccines, which for a large part of its four decades of existence, quietly grew selling specialised drugs, mostly in the gynaecology segment. That quietness was shaken six months ago, replaced by loud headlines. Controlled by US-based